Showing results (2241-2250 of 2,629) with videos related to

Sort By:
Pageof 263
Cell Reports|February 28, 2026
Lipocalin 2 orchestrates resistance to ferroptosis via AXLSabrina Z Wang, J Payton Timken, Ellen S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung CarcinomaD Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.
Brachytherapy|May 16, 2019
The American Brachytherapy Society consensus statement on intraoperative radiation therapyMartin C Tom, Nikhil Joshi, Frank Vicini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled studyE Van Cutsem, T Yoshino, H J Lenz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancerE F Smit, M A Socinski, B P Mullaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
The Oncologist|September 29, 2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patientsTristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, et al.
Nature Biomedical Engineering|January 5, 2021
A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burdenJoseph D Butner, Zhihui Wang, Dalia Elganainy, et al.
Pageof 263